How many investments has Bain Capital Life Sciences made?

Bain Capital Life Sciences has 89 tracked investments, 4 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.

What stage does Bain Capital Life Sciences invest at?

Bain Capital Life Sciences invests at the Series B, Series C, Growth, Late Stage stages.

What sectors does Bain Capital Life Sciences focus on?

Bain Capital Life Sciences focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Bain Capital Life Sciences located?

Bain Capital Life Sciences is headquartered in Boston, US.

Does Bain Capital Life Sciences lead rounds?

Bain Capital Life Sciences has led 4 of the 9 rounds where its role is on record.

Who does Bain Capital Life Sciences co-invest with?

Bain Capital Life Sciences most often shares deals with RA Capital, Bain Capital Double Impact Fund LP, Bain Capital Tech Opportunities, among 106 tracked co-investors.

Bain Capital Life Sciences

Growth equityoperating company · company profile

Boston · Series B–Late Stage · 32 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Bain Capital Life Sciences targets biopharmaceutical, medical device, diagnostic, and life science tool companies globally with a focus on addressing unmet medical needs. The team leverages extensive public and private investing expertise, operating and consulting experience, and deep scientific and medical knowledge to invest at scale and provide strategic support during critical value-creation phases. The firm pursues a science-first diligence approach to build a diverse portfolio of high-impact, value-creating companies in the life sciences sector.

Invests inBiotech Digital Health Healthtech Medical Devices Boston Global New York

Source: firm website, verified Aug 6, 2026.

Stage

Series B–Late Stage

Boston, NY, US

Instruments

Equity

Founded

2016

Last 12 months

7 investments

Tracked investments

Team · 32 people

from the firm's website & public directories

Amir Zamani· Partner· Boston

Amir Zamani is a Partner on the Life Sciences team at Bain Capital, which he joined in 2018. He was previously a Partner at McKinsey & Company, where he worked in the Biopharmaceutical and Medical Products Practice, and earlier was a resident in Plastic Surgery at the University of Pennsylvania. He earned his MD from The Johns Hopkins University School of Medicine and holds a BS in biological sciences and a BA in economics from Stanford University.

Andrew Hack· Partner, Life Sciences· Boston

Andrew Hack is a Partner on the Life Sciences team at Bain Capital, which he joined in 2019. He previously served as Chief Financial Officer of Editas Medicine and as a portfolio manager at Millennium Management running a market-neutral healthcare hedge fund, and earlier worked as a securities analyst at healthcare-focused hedge funds and banks and as Director of Life Sciences at Reify Corporation. He holds an MD and PhD in molecular genetics and cell biology and an AB in biology, all from the University of Chicago.

Nicholas Downing· Partner· Boston

Nicholas Downing is a Partner on the Life Sciences team at Bain Capital, which he joined in 2018. He previously was a resident physician at Brigham and Women's Hospital in Boston and worked as a consultant at McKinsey & Company, serving pharmaceutical, hospital, and financial services clients. He has authored more than 40 peer-reviewed articles and holds a chemistry degree from Harvard College and an MD from Yale University School of Medicine.

Ricky Lijing Sun· Partner· Boston

Ricky Sun is a Partner on Bain Capital's Life Sciences team, which he joined in 2016. Before Bain Capital, he was Director of Corporate Development and Strategy at Biogen, a Vice President at BlackRock, and a healthcare analyst at Citadel, Alyeska Investment Group, Lehman Brothers, and Morgan Stanley; he began his career as a senior scientist at Ironwood Pharmaceuticals. He holds a PhD in chemistry and chemical biology from Harvard, an MBA from NYU Stern, and a BA in chemistry from Berea College.

Adam M. Koppel· Partner· Bostonin

Adam M. Koppel is a Partner on the Life Sciences team at Bain Capital, which he first joined in 2003 and rejoined in 2016, having earlier been part of the firm's Public Equity team focused on healthcare. Between his stints at Bain Capital, he served as EVP of Corporate Development and Chief Strategy Officer at Biogen, and prior to that was an Associate Principal at McKinsey & Company. He holds an MD and PhD in neuroscience and an MBA from the University of Pennsylvania, and an AB and AM in history and science from Harvard University.

Evan Greif· Principal· Boston

Evan Greif is a Principal on the Life Sciences team at Bain Capital, which he joined in 2020. Before that, he worked as an Analyst covering healthcare at Orbis Investments and as an Associate Consultant at Bain & Company. He holds a BA in applied mathematics and an MA in statistics from Harvard University, along with a MAST in pure mathematics from Cambridge University.

John Trzupek· Managing Director· Boston

John Trzupek joined Bain Capital in 2025 as a Managing Director on the Life Sciences team. He previously served as COO and CFO at Abata Therapeutics and Chief Business Officer at KSQ Therapeutics, and held business and scientific roles at Pfizer, including Director of Strategy for inflammation and immunology. He began his career as a Research Fellow at Memorial Sloan-Kettering Cancer Center.

Lei Meng· Managing Director· Boston

Lei Meng is a Managing Director on the Life Sciences team at Bain Capital, which she joined in 2024. She previously worked in therapeutics private investments at Avidity Partners and held roles in marketing analytics and business development at Allergan, as well as earlier positions at Merck & Co, Forest Labs, McKinsey & Company, and Samlyn Capital. She holds an MA in chemistry from Harvard University, an MBA from INSEAD, and a BA in biochemistry from Barnard College, Columbia University.

Leonard Feiner· Principal· Boston

Leonard Feiner, MD, PhD, is a Principal on the Life Sciences team at Bain Capital, which he joined in 2021. Before that, he worked as a vitreoretinal surgeon and served as principal investigator on over 50 clinical trials covering conditions such as macular degeneration, diabetic macular edema, and retinal vein occlusion. He holds a degree in mechanical and aerospace engineering from Princeton University and an MD/PhD from the University of Pennsylvania, with an ophthalmology residency at Penn and a surgical retina fellowship at Washington University in St. Louis.

Matthew Calistri· Managing Director· Boston

Matthew Calistri is a Managing Director in the Portfolio Group of Bain Capital's Life Sciences business, which he joined in 2024. He previously spent four years at Cerevel Therapeutics, serving as VP of Investor Relations and VP of Corporate Strategy, and held investor relations roles at Sage and Biogen. Earlier in his career he worked in financial services at Gerson Lehrman Group, ITG, UBS, Bankers Trust, and E&Y, and he holds an MBA in finance from the University of Chicago Booth School of Business and a BS in accounting from Fordham University.

Renjie Wang· Managing Director· Shanghai

Renjie Wang is a Managing Director on the Life Sciences team at Bain Capital, which she joined in 2014. She previously worked at Hony Capital, where she closed buyout, minority investment, and privatization transactions in the healthcare sector. She holds a master of finance from Peking University and a BA in economics from Fudan University.

Will Cozean· Managing Director· Melbourne

Will Cozean is a Managing Director on Bain Capital's Life Sciences team, which he joined in 2013. He previously worked on the firm's North America Private Equity team in the Healthcare vertical, as well as its Industrial and Technology verticals, and earlier was a consultant at McKinsey & Company in Atlanta. He holds an MBA from Harvard Business School (Baker Scholar) and a BS in commerce from the University of Virginia (Jefferson Scholar).

Benjamin Lund· Principal· Boston, Massachusettsin

Drew Field· Principal· Bostonin

Drew Field is a Principal on the Life Sciences team at Bain Capital, which he joined in 2020. Before that, he was a management consultant at Bain & Company in New York, working with healthcare and private equity clients, and previously held commercial strategy and investor relations roles at a biotech company. He holds a BA in biology and economics from Dartmouth College.

Jonah Cashdan· Principal· New Yorkin

Jonah Cashdan is a Principal on the Life Sciences team at Bain Capital, which he joined in 2018. He previously worked in J.P. Morgan's healthcare investment banking group on M&A and financings for pharmaceutical, biotech, and medtech clients, and earlier studied synaptic physiology and sensory system development in labs at Georgetown University. He holds a BS in Neurobiology from Georgetown University.

Alyson Goff· Associate· Boston

Alyson Goff joined Bain Capital in 2025 as an Associate in the Portfolio Group for the Life Sciences business. Before that, she worked as a management consultant at Guidehouse in Boston, advising life-science sector clients on strategic initiatives. She holds an MS in biotechnology enterprise and entrepreneurship from Johns Hopkins University and a BA in biology from Boston University.

Amarilice Young· Associate General Counsel, Life Sciences· Boston

Amarilice Young joined Bain Capital in 2025 as Associate General Counsel for Life Sciences. She was previously a partner in the Life Sciences group at Goodwin Procter LLP. She holds a JD from University of Pennsylvania Law School and a BA in American Studies from Cornell University, and is a member of the Massachusetts and New York state bars.

Chiaka Ibe· Associate· Boston

Chiaka Ibe is an Associate on the Bain Capital Life Sciences team, which she joined in 2024. She was previously a management consultant at Bain & Company, advising clients in the Private Equity Group and Healthcare & Life Sciences practice, and worked as an analyst on the Health & Life Sciences team at Gates Ventures. She holds a BA in international health and human biology from Brown University.

Daniyal Sachee· Associate· Boston

Daniyal Sachee is an Associate on the Life Sciences team at Bain Capital, which he joined in 2025. He previously worked in the healthcare investment banking group at Goldman Sachs, advising on M&A, debt and equity financings, and royalty monetizations across the biotech and pharmaceutical sectors, and earlier conducted research on rare epilepsy-related disorders at Boston Children's Hospital. He holds a BA in Computational Neuroscience from Harvard.

Greg Koskinas· Chief Financial Officer, Life Sciences· Boston

Greg Koskinas is Chief Financial Officer for the Life Sciences business at Bain Capital, which he first joined in 2000 and rejoined in 2024. He was an original member of the firm's Absolute Return Capital business, overseeing trading and operational functions, and earlier worked in the finance group of the Public Equity business. Before returning to Bain Capital, he served as Chief Operating Officer and Chief Compliance Officer at ThornTree Capital Partners. He holds a BA in business and economics from Lafayette College.

Isaac Cheng· Vice President· Boston

Isaac Cheng is a Vice President on the Life Sciences team at Bain Capital, which he joined in 2024. He previously held business development and strategy roles in the pharmaceuticals unit at Johnson & Johnson, and evaluated business development and licensing opportunities across pharmaceuticals, MedTech, and services at AbbVie (via its acquisition of Allergan). He began his life sciences career as a management consultant at ZS Associates.

Jay Corrigan· Group Chief Financial Officer, Private Markets· Boston

Jay Corrigan is a Partner and Group Chief Financial Officer for Private Markets at Bain Capital, which he joined in 1996. He oversees the finance teams across Private Equity, Venture, Crypto, Double Impact, Life Sciences, Tech Opportunities, and Real Estate, and also serves as CFO for Double Impact; he previously was CFO for Global Private Equity. Before Bain Capital he spent three years at Ernst & Young, and he holds a BS in accounting from Fordham University.

Jennie Daisak· Vice President· Boston

Jennie Daisak is a Vice President on the Life Sciences team at Bain Capital, which she joined in 2021. Before Bain Capital, she worked in J.P. Morgan's healthcare investment banking group, advising biotechnology and pharmaceutical clients on M&A and debt/equity financings. She graduated from the University of Pennsylvania's Vagelos Program in Life Sciences & Management, earning a BA in biology and a BS in economics from the Wharton School with a finance concentration.

Kristen Deftos· Partner and Head of Human Resources, Double Impact, Life Sciences, Real Estate & Tech Opportunities· Boston

Kristen Deftos joined Bain Capital in 2012 and serves as Partner and Head of Human Resources across the firm's Double Impact, Life Sciences, Real Estate, and Tech Opportunities teams, overseeing talent acquisition, performance management, and organizational development. Before Bain Capital, she worked at Wellington Management Company in Boston in HR relationship management and global talent acquisition roles, and earlier held HR and recruiting positions at J.P. Morgan in New York. She holds an AB from Bowdoin College and an MA in organizational psychology from Columbia University Teachers' College.

Melaku Arega· Vice President· Boston

Melaku Arega is a Vice President on the Life Sciences team at Bain Capital, which he joined in 2022. Before that, he attended Harvard Medical School, completing clinical training at Beth Israel Medical Center and other Harvard-affiliated hospitals, and conducted research on cancer care disparities. He holds an MD from Harvard Medical School, an MBA from Harvard Business School, and a BS in neuroscience and molecular & cellular biology from Johns Hopkins University.

Melissa Danforth· General Counsel, Life Sciences· Boston

Molly Lawrence· Vice President, Human Resources, Life Sciences· Boston

Molly Lawrence joined Bain Capital in 2025 as a Vice President of Human Resources, where she leads recruiting, development, and engagement efforts for the Life Sciences team. She previously served as Vice President of Talent Management and Development at Audax Private Equity and held talent roles at Bain & Company. She holds a BA from Dartmouth College.

Sharad Goyal· Senior Vice President and Head of IT, Private Markets· Boston

Sharad Goyal is Senior Vice President and Head of IT for Private Markets at Bain Capital, which he joined in 2007. Before Bain Capital, he held technology consulting roles in the Global Capital Markets division of Sapient (now Publicis.Sapient). He holds an MBA in finance from Management Development Institute in India, along with a master's in computer science and a bachelor's in finance.

Shuvam Chaudhuri· Associate· Boston

Shuvam Chaudhuri is an Associate on the Life Sciences team at Bain Capital, which he joined in 2023, having previously served as a Life Sciences Fellow. He completed his doctoral research at Northwestern University, studying transcriptional mechanisms of immune cell differentiation in cancer, infection, and autoimmunity, and earlier worked in antiviral drug discovery at Janssen Research and Development.

Harris Weber· Vice President· New Yorkin

Julie Yang· Associate· Boston, Massachusetts

Michael Cooney· Vice President· Boston

Michael Cooney is a Vice President on the Life Sciences team at Bain Capital, which he joined in 2021 after serving as a Life Sciences fellow. Before Bain Capital, he was a graduate student researcher in the Department of Genetics at Harvard Medical School, focusing on genomic instability and epigenetic dysfunction in aging, and earlier worked at Genocea Biosciences on pre-clinical and clinical research into T-cell-inducing vaccines. He holds a PhD in biological and biomedical sciences from Harvard University and BS degrees in biology and biotechnology from Tufts University.

What they invest in

from 57 of 94 portfolio companies

Biotech ×46Healthtech ×37Medical Devices ×17Digital Health ×5AI & Machine Learning ×4Deep Tech ×3Fintech ×2Future of Work ×2

HQs:United States×39Switzerland×1United Kingdom×1

Who they back

founder profiles across 17 portfolio companies

53%

solo founders

9 of 17 mapped founding teams

<1 yr

old at investment

median across 11 dated deals

Founding team size:solo founder×92 founders×73 founders×1

Investments · 94 tracked

founders shown can be your intro path

By year:2026 · 5 2025 · 2 2022 · 1 2021 · 4 2020 · 3 2019 · 3 2017 · 1 2016 · 1 2015 · 222 dated

Solid Biosciencessolidbio.comNASDAQ: SLDBOct 2020

Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.

BiotechHealthtechCharlestown, US

Stephen DiPalma(Executive Officer)Alexander (Bo) Cumbo(Executive Officer, Director)Carl Morris(Executive Officer)Martin Freed(Director)Paul Herizch(Executive Officer)Robert Huffines(Director)

Board seatAdam M. Koppel· per SEC Form D

Co-investorsForesite Capital RA Capital

Xilio Therapeuticsxiliotx.com inNASDAQ: XLOFeb 2021

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)

Board seatAndrew Hack· per SEC Form D

Co-investorsBay City Capital F-Prime Capital M Ventures MRL Ventures Fund RA Capital RiverVest Venture Partners +4 more

AlkermesNASDAQ: ALKS

Amylyx PharmaceuticalsNASDAQ: AMLX

BiotechCambridge, US

Joshua Cohen(Executive Officer, Director)Justin Klee(Director)

BoardStephen D. Chubb(Director)George M. Milne, PH.D.(Director)

Arcutis BiotherapeuticsNASDAQ: ARQTOct 2019

BiotechWestlake Village, US

Alexander Asam(Director)Ricky Sun(Director)Todd Franklin Watanabe(Executive Officer, Director)

BoardPatrick Heron(Director)inDaniel Estes(Director)inJonathan Silverstein(Director)

Co-investorsRA Capital Frazier Life Sciences

Atea Pharmaceuticalsateapharma.comNASDAQ: AVIR

Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).

BiotechHealthtechBoston, US

Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)

BoardBruno Lucidi(Director)Evgeny Zatsev(Director)Frank Yu(Director)Gerald Chan(Director)Bruce Polsky(Director)

Co-investorsRA Capital

C4 Therapeuticsc4therapeutics.com in 𝕏NASDAQ: CCCCDec 2015

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.

BiotechCambridge, US

BoardMarc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)Bihua Chen(Director)William M. Scalzulli(Director)

Co-investors3E Bioventures Capital Nextech Invest RA Capital

Cabaletta BioNASDAQ: CABA

Disc Medicinediscmedicine.comNASDAQ: IRON

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)Jean Franchi(Chief Financial Officer)Jonathan Yu(Chief Operating Officer)Will Savage(Chief Medical Officer)Pamela Stephenson(Chief Commercial Officer)Steve Caffé(Chief Regulatory Officer)

Co-investorsAccess Biotechnology Atlas Venture Foresite Capital Frazier Life Sciences OrbiMed

Freenomefreenome.com inNASDAQ: FRNMOct 2015

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon

Riley Ennis(Co-Founder and Chief Product Officer)Charles Roberts(Director)inGabriel Otte(Director)in

BoardStuart Lawson(Director)

Co-investorsRA Capital AME Cloud Ventures Andreessen Horowitz Artis Ventures Asset Management Company Averin Capital +8 more

HeartFlowheartflow.com in 𝕏NASDAQ: HTFL

Heartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD).

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesRedwood City, US

Christopher K. Zarins(Executive Officer, Director)Charles A. Taylor(Executive Officer, Director)Nicky Espinosa Hayes(Executive Officer)John Stevens(Executive Officer, Director)H. Baird Radford, III(Executive Officer)John Farquharin

Co-investorsBlue Venture Funds Emergent Medical Partners, LLP Khosla Ventures Lifeforce Capital Lotus Capital Silver Lake Partners +1 more

Invivydinvivyd.comNASDAQ: IVVD

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsForesite Capital MRL Ventures Fund Premji Invest

Kestra Medical Technologieskestramedical.com inNASDAQ: KMTS

Kestra Medical develops wearable defibrillator technology aimed at protecting patients at risk of sudden cardiac arrest through rapid defibrillation.

HardwareHealthtechMedical Devices

Co-investorsAndera Partners Longitude Capital

Kymera Therapeuticskymeratx.com in 𝕏NASDAQ: KYMR

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Nello Mainolfi(Founder)in

Co-investorsAtlas Venture Avoro Capital Advisors Bessemer Venture Partners Hatteras Venture Partners MRL Ventures Fund Nextech Invest +3 more

Kyverna TherapeuticsNASDAQ: KYTXNov 2021

BiotechEmeryville, US

Brian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)James Chung(Executive Officer)

Nateranatera.com in 𝕏NASDAQ: NTRA

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)Jonathan Sheena(Founder)in

Co-investorsCheyenne Ventures Claremont Creek Ventures Foresite Capital Harmony Partners Lightspeed Venture Partners RA Capital +1 more

Replimune GroupNASDAQ: REPL

Co-investorsForesite Capital

Revolution MedicinesNASDAQ: RVMD

BiotechRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)

BoardLaurence Lasky(Director)Alexis Borisy(Director)Elizabeth Anderson(Director)Michael Bonney(Director)

Co-investorsForesite Capital Nextech Invest Third Rock Ventures

Savarasavarapharma.com inNASDAQ: SVRADec 2019

Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases.

BiotechHealthtechMedical DevicesAustin, US

Matt Pauls(Chair of the Board of Directors and Chief Executive Officer)Mike Ciesla(Executive Officer)Badrul Chowdhury(Executive Officer)Richard J. Hawkins(Director)An van Es-Johansson(Director)Ricky Sun(Director)

Co-investorsCentral Texas Angel Network Green Park & Golf Ventures Keiretsu Forum Moore Venture Partners New Enterprise Associates (NEA)

Upstream Bioupstreambio.com in 𝕏NASDAQ: UPB

Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling.

BiotechHealthtech

Rand Sutherlandin

Co-investorsAccess Biotechnology Decheng Capital OrbiMed TCG Crossover

X4 PharmaceuticalsNASDAQ: XFOR

Abcuroabcuro.comAug 2026✓ verified

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)Alex Martin(Chief Executive Officer)

Co-investorsNew Enterprise Associates (NEA)RA Capital Samsara BioCapital Sanofi Ventures Mass General Brigham Ventures REDMILE +8 more

Merida Biosciencesmeridabio.com in✓ verified

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Michael Naill(Senior Vice President, Process and Product Development)Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)

Co-investorsThird Rock Ventures Biotechnology Value Fund GV (Google Ventures)

Swixx Biopharmaswixxbiopharma.com✓ verified

Swixx BioPharma is a commercialization partner that acts as the local subsidiary for biopharma, OTC, and medical device companies in markets they choose not to enter directly, handling market access, regulatory, and commercial operations without its own R&D or manufacturing.

BiotechHealthtechMedical DevicesBaar, CH

Co-investorsHBM Partners Mérieux Equity Partners SK Capital Partners

Aptinyxaptinyx.comDec 2017

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Board seatAdam M. Koppel· per SEC Form D

Co-investorsFrazier Life Sciences Latterell Venture Partners Longitude Capital OUP (Osage University Partners)

Areteia Therapeuticsareteiatx.comJun 2022Defunct

Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

BiotechChapel Hill, US

Robin Walker(Executive Officer)Christopher Courts(Executive Officer)Jorge Bartolome(Executive Officer, Director)

BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)

Board seatAdam M. Koppel· per SEC Form D

Co-investorsARCH Venture Partners GV (Google Ventures)

Cardurion Pharmaceuticals, Inc.Oct 2021

BiotechBurlington, US

Michael Mendelsohn(Executive Officer, Director)

BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)in

Board seatNicholas DowningAdam M. Koppel· per SEC Form D

Co-investorsBain Capital NEA Secondary Polaris Partners Third Rock Ventures

JenaValvejenavalve.comJan 2020

JenaValve manufactures the Trilogy Transcatheter Heart Valve System, an FDA-approved device for treating severe aortic regurgitation in high-risk patients who cannot undergo surgical valve replacement.

HealthtechMedical DevicesIrvine, US

Victoria Carr-Brendel(Executive Officer, Director)Hans-Reiner Figulla(Director)David Drachman(Executive Officer, Director)

BoardArnd Kaltofen(Director)inErik Amble(Director)Peter Barrett(Director)

Board seatAndrew Hack· per SEC Form D

Co-investorsAndera Partners VI Partners

A Place for Momfiscloudservices.com

Vernon Hills, US

Jonathan Stevens(Executive Officer)Thomas Richards(Executive Officer, Director)Christine Leahy(Executive Officer)Dennis Berger(Executive Officer)Neal Campbell(Executive Officer)Christina Rother(Executive Officer)

Co-investorsBain Capital Double Impact Fund LP Bain Capital Tech Opportunities Blue Sea Capital Bootstrap Europe Clayton Dubilier & Rice Core Venture Capital +12 more

ADARx Pharmaceuticals

Co-investorsSR One Capital Management

AdvanCelladvancell.com.au inJun 2026

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)Philina Lee(Executive Officer, Director)Aaron Pickett(Executive Officer)

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsCatalio Capital Management, LP Proto Axiom SV Health Investors Tenmile Abingworth Ally Bridge Group +2 more

Afferaaffera.com 𝕏

Affera develops a medical technology platform for treating cardiac arrhythmias, including atrial fibrillation, using innovative ablation solutions.

HealthtechMedical DevicesNewton, US

Doron Harlev(CEO, Founder)

Co-investorsElysia Capital

Affinivaxaffinivax.com in 𝕏

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)Kamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsEcoR1 Capital Foresite Capital

Aiolos Bioaiolosbio.com in 𝕏

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsRA Capital Sofinnova Ventures

Alkeuspharmaalkeuspharma.com in 𝕏

Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Carlos Quezada-Ruiz(Chief Medical Officer)

Co-investorsSofinnova Ventures TCG Crossover

Amunix Pharmaceuticals

Angitia

Annexonannexonbio.com

Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases.

BiotechHealthtechSo. San Francisco, US

Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)Thomas Wiggans(Director)Ricky Sun(Director)Ted Yednock(Executive Officer)

Co-investorsCorrelation Ventures New Enterprise Associates (NEA)Clarus

Apreo

Atsena

Avistone Pharmaceuticals

Bain Capitalbaincapital.com in 𝕏

Bain Capital is a private investment firm founded in 1984 that invests in and partners with companies to drive growth and improvement.

Sector AgnosticBoston, US

Co-investorsBain Capital Double Impact Fund LP Bain Capital Tech Opportunities BCI

Bain Capital Creditbaincapitalcredit.com

Bain Capital Credit is a credit investment manager that evaluates opportunities across the credit spectrum, offering commingled funds and separate accounts with varying liquidity parameters, asset exposures, and geographic concentrations.

Fintech

Co-investorsBain Capital Double Impact Fund LP Bain Capital Tech Opportunities Bain Capital Venture

Bain Capital Private Equitybaincapitalprivateequity.com in 𝕏

Bain Capital Private Equity is an investment firm operating a private equity portfolio, with an investor portal for account holders.

Co-investorsBain Capital Double Impact Fund LP Bain Capital Tech Opportunities Bain Capital Venture

Bain Capital Special Situationsbaincapitalspecialsituations.com

Bain Capital Special Situations provides customized capital solutions across credit, private equity, and real assets, structuring investments for individual opportunities with a focus on downside protection.

Fintech

Co-investorsBain Capital Double Impact Fund LP Bain Capital Tech Opportunities Bain Capital Venture

Bain Double Impact IIbaincapitaldoubleimpact.com

Co-investorsBain Capital Tech Opportunities Bain Capital Venture Blue Haven Initiative

Baincapitalrealestatebaincapitalrealestate.com

Bain Capital Real Estate is a real estate investment platform that applies a value-add approach to complex, demand-driven assets.

PropTech

Co-investorsBain Capital Double Impact Fund LP Bain Capital Tech Opportunities Bain Capital Venture

Beelinebeeline.com inJun 2026 · $126.3M

Beeline provides a Vendor Management System (VMS) and extended workforce platform that helps enterprises manage their non-employee and external labor, covering compliance, cost control, and risk.

Enterprise SoftwareFuture of WorkHR TechSaaS

Co-investorsAcadian Ventures Management, Llc

Beeline Medicinesbeelinemedicines.com

Beeline Medicines is a clinical-stage biotechnology company developing precision therapies that target the underlying drivers of immune dysfunction for people living with autoimmune and inflammatory diseases such as lupus and psoriasis.

BiotechHealthtechStamford, US

Co-investorsBain Capital

Caldera Therapeutics, Inc.Jan 2026

BiotechCambridge, US

Praveen Tipirneni(Executive Officer, Director)

BoardMichelle Doig(Director)inAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)

Co-investorsAtlas Venture Janus Henderson Investors LAV Omega Funds venBio Global Strategic venBio Partners +1 more

Cerevasccerevasc.comMay 2020

CereVasc is developing the eShunt System, a minimally invasive device intended to treat communicating hydrocephalus in children and adults as an alternative to invasive neurosurgical procedures.

BiotechHealthtechMedical DevicesAuburndale, US

Carl Heilman(Director)Daniel Levangie(Executive Officer, Director)Leslie Teso-Lichtman(Executive Officer)Frederick Callori(Director)Patrick Sullivan(Director)Aaron Levangie(Executive Officer)

Cerevel Therapeutics

Co-investorsFrazier Life Sciences

Cidara Therapeuticscidara.com in 𝕏

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)Kevin Forrest(Executive Officer)Dirk Thye(Executive Officer)Ken Bartizal(Executive Officer)Paul Daruwala(Executive Officer)

Co-investors5AM Ventures Aisling Capital Frazier Life Sciences RA Capital Vivo Capital Canaan Partners +1 more

Constellation Pharmaconstellationpharma.com in 𝕏acquired by Novartis

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)James E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)Tom Maniatis(Director)

Co-investorsAvoro Capital Advisors Venrock The Column Group Third Rock Ventures

Dianthus

Dicerna Pharmaceuticalsdicerna.com 𝕏

The site presents corporate and investor news relating to Novo Nordisk, a pharmaceutical company, including financial reports and clinical trial results for products such as GLP-1 medicines and the hemophilia A treatment denecimig (Mim8).

BiotechHealthtech

Co-investorsAccess Biotechnology

Dynavax Technologies

Emalex Biosciencesemalexbiosciences.com in 𝕏

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome.

BiotechMedical Devices

Co-investorsParagon Biosciences LLC

EyeBioacquired by Merck

Global company developing next-generation eye disease therapies; acquired by Merck & Co.

Co-investorsJeito Capital MRL Ventures Fund SV Health Investors

FIS

Exits · 25

IPOs and acquisitions across the tracked portfolio

Solid BiosciencesNASDAQ: SLDBXilio TherapeuticsNASDAQ: XLOAlkermesNASDAQ: ALKSAmylyx PharmaceuticalsNASDAQ: AMLXArcutis BiotherapeuticsNASDAQ: ARQTAtea PharmaceuticalsNASDAQ: AVIRC4 TherapeuticsNASDAQ: CCCCCabaletta BioNASDAQ: CABADisc MedicineNASDAQ: IRONFreenomeNASDAQ: FRNMHeartFlowNASDAQ: HTFLInvivydNASDAQ: IVVDKestra Medical TechnologiesNASDAQ: KMTSKymera TherapeuticsNASDAQ: KYMRKyverna TherapeuticsNASDAQ: KYTXNateraNASDAQ: NTRAReplimune GroupNASDAQ: REPLRevolution MedicinesNASDAQ: RVMDSavaraNASDAQ: SVRAUpstream BioNASDAQ: UPBX4 PharmaceuticalsNASDAQ: XFORConstellation Pharmaacq. by NovartisEyeBioacq. by MerckGynesonicsacq. by HologicJnana Therapeuticsacq. by Otsuka

Portfolio news

latest coverage across their companies

Merck Stock Jumps on Phase 3 Cancer Vaccine Win as Keytruda Risk Eases

Cidara Therapeutics · tradingkey.com · Aug 20, 2026

Abcuro secures $66m to support clinical trial of ulviprubart for IBM

Abcuro · clinicaltrialsarena.com · Aug 19, 2026

Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick

Arcutis Biotherapeutics · streetinsider.com · Aug 19, 2026

Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right? - Simply Wall St News

Nurix Therapeutics · simplywall.st · Aug 18, 2026

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Disc Medicine · prnewswire.com · Aug 18, 2026

HeartFlow: An Impressive MedTech Growth Play (NASDAQ:HTFL) | Seeking Alpha

HeartFlow · seekingalpha.com · Aug 16, 2026

Xilio Therapeutics (NASDAQ:XLO) Announces Quarterly Earnings Results - Ticker Report

Xilio Therapeutics · tickerreport.com · Aug 15, 2026

RA Capital reports 9.99% stake in C4 Therapeutics | CCCC SEC Filing - Form SCHEDULE 13G/A

C4 Therapeutics · stocktitan.net · Aug 14, 2026

Fund performance · per public LP disclosures

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Bain Capital Life Sciences Fund IV. L.P.LPs: New Jersey Division of Investment, California Public Employees' Retirement System, Maryland State Retirement and Pension System	2024	—	—	0.00x	0.00x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Public market activity · per SEC filings

what is this? ⓘ

4 insider ownership filings (Forms 3/4/5)

at Kailera Therapeutics, Inc. (KLRA), Olema Pharmaceuticals, Inc. (OLMA)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Bain Capital Life Sciences made?: Bain Capital Life Sciences has 89 tracked investments, 4 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.
What stage does Bain Capital Life Sciences invest at?: Bain Capital Life Sciences invests at the Series B, Series C, Growth, Late Stage stages.
What sectors does Bain Capital Life Sciences focus on?: Bain Capital Life Sciences focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Bain Capital Life Sciences located?: Bain Capital Life Sciences is headquartered in Boston, US.
Does Bain Capital Life Sciences lead rounds?: Bain Capital Life Sciences has led 4 of the 9 rounds where its role is on record.
Who does Bain Capital Life Sciences co-invest with?: Bain Capital Life Sciences most often shares deals with RA Capital, Bain Capital Double Impact Fund LP, Bain Capital Tech Opportunities, among 106 tracked co-investors.

Co-investors · 11

RA Capital

RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.

Both backed · 16

Arcutis Biotherapeutics Atea Pharmaceuticals C4 Therapeutics Freenome Natera Solid Biosciences Xilio Therapeutics Abcuro Aiolos Bio Cidara Therapeutics Olema Synthekine ViacyteInflaRxJnana TherapeuticsNimbus Therapeutics

Bain Capital Venture

Bain Capital is a global private investment firm operating across private equity, growth and venture capital, credit, capital solutions, and real assets, with offices in North America, Europe, and Asia-Pacific. The firm invests across industries and business life cycles, from seed-stage venture investments through buyouts, and integrates sustainability commitments into its portfolio governance.

Both backed · 8

Bain Capital Credit Bain Capital Private Equity Bain Capital Special Situations BaincapitalrealestateBain Double Impact IIInsuranceJapan - 日本Tech Opportunities

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 4

Freenome Areteia Therapeutics Merida Biosciences Syremis Therapeutics

$250K – $50M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that backs and helps build transformational companies, with a strong focus on the life sciences and biotech sector.

Both backed · 1

Areteia Therapeutics

$50K – $250M

New Leaf Venture Partners

New Leaf Venture Partners is a venture capital firm investing in innovative healthcare companies.

Both backed · 1

Abcuro

Agent Capital

Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.

Both backed · 1

Freenome

SV Angel

SV Angel is an investment firm that partners with and supports founders building transformative companies, providing long-term backing and close advisory relationships.

Unknown Ventures

Unknown Ventures is a venture studio based in Austin that provides funding and operational support to early-stage startups at the pre-seed to Series A stage. The firm backs founders seeking to create innovative solutions that improve human experience.

General Atlantic

General Atlantic is a global investment firm that partners with entrepreneurs and category-leading companies, providing patient capital, operational expertise, and a global platform to support long-term growth.

$10M – $1B

Triatomic Capital

Triatomic Capital is an investment firm focused on 'century defining' themes across advanced technology areas including AI infrastructure, semiconductors, materials, robotics, and energy.

$100K – $1M

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Firms observed investing alongside Bain Capital Life Sciences, from public investor directories. Shared companies are the overlap with Bain Capital Life Sciences's recorded portfolio.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Pontifax Venture Capital

Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.

$6.3M – $128M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Growth Investors & VC Firms Series B Investors & VC Firms Investors & VC Firms in Global Healthtech Investors & VC Firms Late Stage Investors & VC Firms Series C Investors & VC Firms Growth Investors & VC Firms in North America Series B Investors & VC Firms in North America Healthtech Investors & VC Firms in North America Biotech Investors & VC Firms